Details of the Drug
General Information of Drug (ID: DMIZQW6)
| Drug Name |
LYSICAMINE
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Lysicamine; Oxonuciferine; 15444-20-9; CCRIS 3813; NSC 628003; BRN 1486372; UNII-6L30DD6R7O; CHEMBL510090; 6L30DD6R7O; CHEBI:70650; 1,2-Dimethoxy-7H-dibenzo(de,g)quinolin-7-one; NSC628003; 7H-Dibenzo(de,g)quinolin-7-one, 1,2-dimethoxy-; Noraporphin-7-one, 4,5,6,6a-tetradehydro-1,2-dimethoxy-; 7H-Dibenzo[de,g]quinolin-7-one, 1,2-dimethoxy-; 5-21-13-00382 (Beilstein Handbook Reference); (+)-ushinsunine-beta-N-oxide; SCHEMBL2046474; AC1L3V30; DTXSID00165628; MolPort-044-754-181; DPBMWJXWUINLQT-UHFFFAOYSA-N; BDBM50292452
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 291.3 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.5 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


